Dr. Lal PathLabs Q2 FY26 Results: Revenue at Rs 731 Cr, 10.7% Growth YoY

DSIJ Intelligence-2Categories: Mindshare, Trendingprefered on google

Dr. Lal PathLabs Q2 FY26 Results: Revenue at Rs 731 Cr, 10.7% Growth YoY

The stock price is up by 36 per cent, up from the 52-week high.

Dr. Lal PathLabs Limited announced its standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Q2 FY26).

For Q2 FY26, the company reported consolidated revenue of Rs 731 crore, marking a growth of 10.7 per cent year-on-year. EBITDA stood at Rs 224 crore, up by 10.8 per cent, with the EBITDA margin maintained at 30.7 per cent, showing no change compared to the same quarter last year. Profit After Tax (PAT) rose 16.4 per cent to Rs 152 crore, while the PAT margin improved to 20.8 per cent from 19.8 per cent in Q2 FY25. Earnings per share (EPS) increased 16.2 per cent to Rs 18.1.

For the first half of FY26 (FH26), revenue increased by 11.0 per cent, and PAT grew by 20.0 per cent compared to the previous year.

DSIJ’s Tiny Treasure highlights Small-Cap stocks with massive growth potential, giving investors a ticket to India’s emerging market leaders. Download Service Note

In corporate developments, the Board of Directors approved an interim dividend of Rs 7 per share for Q2 FY26. Additionally, the company announced a 1:1 bonus issue, meaning one bonus share will be issued for every one share held on the record date.

As of March 31, 2025, Dr. Lal PathLabs operated a nationwide network of 298 clinical laboratories, including the National Reference Lab in Delhi and regional labs in Kolkata, Bangalore, and Mumbai. The network also includes 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs), reinforcing its strong operational footprint across India.

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. 

The stock price is up by 36 per cent, up from the 52-week high.

Disclaimer: This article is for informational purposes only and is not intended as investment advice.